ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Our results clearly showed that deficiency in p38α greatly enhanced imatinib-induced therapeutic effects in growth suppression and apoptotic cell death in two BCR-ABL-positive CML-derived leukemia cells, K562 and KBM5.